IL11 and neoplasm: H3K9la enhances the expression of interleukin-11 (IL-11), which subsequently triggers immune checkpoint activation through the JAK2/STAT3 signaling pathway, ultimately impairing CD8+ T cell activity and facilitating tumor growth.